24 February 2014 in International Forum of Allergy & Rhinology
IKIlbilge Hacer Ertoy Karagöl
Ilbilge Hacer Ertoy Karagöl
+2
1 November 2012 in Allergy and Asthma Proceedings
IKIlbilge Hacer Ertoy Karagol
Ilbilge Hacer Ertoy Karagol
+1
Epinephrine is an essential medication for the treatment of anaphylaxis. Factors associated with autoinjector design may have a role in its correct use. We compared a new and old epinephrine autoinjector with respect to correct autoinjector use. We invited all interns of the 2011‐2012 training period in our medical school. The participants were randomly assigned into two groups. After all participants were given a three-step written and visual instruction sheet about epinephrine autoinjector use, they were asked to show its use either with the old or the new epinephrine autoinjector trainer. The old and new trainers, which were exactly identical to the original epinephrine autoinjectors except for the medication and needle, were used. The performance of each participant was assessed with a standardized scoring system. Among 220 invited interns, 180 (81.8%) were enrolled. The number of participants correctly showing the use of epinephrine autoinjectors and the mean total score did not differ significantly between the two groups (p = 0.639 and p = 0.233, respectively). Significantly fewer participants had unintentional injections in the new compared with the old epinephrine autoinjector group (p < 0.001). When all assessment steps are considered, only the rate of placing a wrong tip into the outer thigh was significantly lower in the new compared with the old epinephrine autoinjector group (p < 0.05). The new epinephrine autoinjector is more effective in unintentional injection injuries than the old one; however, it still does not fulfill the criteria of an ideal epinephrine autoinjector.
11 March 2013 in Journal of Asthma
To assess and compare management preferences of physicians for moderate and severe acute asthma based on case scenarios and to determine the factors influencing their decisions. A questionnaire based on the Global Initiative on Asthma (GINA) guideline and comprising eight questions on management of acute asthma was delivered to participants of two national pediatric congresses. Management of moderate and severe acute asthma cases was evaluated by two clinical case scenarios for estimation of acute attack severity, initial treatment, treatment after 1h, and discharge recommendations. A uniform answer box comprising the possible choices was provided just below the questions, and respondents were requested to tick the answers they thought was appropriate. Four-hundred and eighteen questionnaires were analyzed. All questions regarding moderate and severe acute asthma case scenarios were answered accurately by 15.8% and 17.0% of physicians, respectively. The initial treatment of moderate and severe cases was known by 100.0% and 78.2% of physicians, respectively. Knowledge of the appropriate plan for treatment after 1h was low both for moderate (45.0%) and severe attacks (35.4%). Discharge recommendations were adequate in 32.5% and 70.8% of physicians for moderate and severe attacks, respectively. Multiple logistic regression analysis revealed that working at a hospital with a continuing medical education program was the only significant predictor of a correct response to all questions regarding severe attacks (p = .04; 95%CI, 1.02-3.21). No predictors were found for information on moderate attacks. Pediatricians have difficulty in planning treatment after 1 hour both for moderate and severe asthma attacks. Postgraduate education programs that target physicians in hospitals without continuing medical education facilities may improve guideline adherence.
10 February 2006 in Pediatric Pulmonology
1 January 2010 in Turkiye Klinikleri Journal of Medical Sciences
Human monoclonal anti-IgE antibody (omalizumab) is recently recommended at the fifth step of international asthma guidelines for the treatment of patients older than 12 years of age who have severe persistent allergic asthma uncontrolled despite treatment with high-dose inhaled corticosteroid (>800 µgr/day) in combination with a long-acting ?2-agonist and oral leukotriene receptor antagonist and have serum total Ig E between 30-700 IU/ml. We started omalizumab as add-on treatment to a severe persistent asthmatic case who had two severe asthma attacks in the last three-month period, one of which was complicated with pneumomediastinium. This is the first experience with omalizumab in a child with severe asthma reported from our country. The first seven-month of omalizumab treatment resulted in significant improvements in quality of life and pulmonary functions as well as reductions in inhaled corticosteroid dose and daily symptom scores.